TICKERNERD
Menu
TLSITLSIHealthcare · Medical Devices

TLSI Stock Forecast: TriSalus Life Sciences, Inc. Price Predictions for 2026-2027

Last close, 30 Oct 2026
$3.70
−4.15% on the day

The 5 Wall Street analysts covering TriSalus Life Sciences, Inc. hold a median 12-month price target of $11 — +197.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 28 of 100 as at 31 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$227.8M
Ticker Nerd rank
28/ 100
Median analyst target
$11
Analysts covering
5
Revenue$11.4M+1.7% y/y
Operating income−$9.8M
Net income−$9.2M
Free cash flow−$10.2M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+3.1%
1M
−14.2%
YTD
−47.0%
1Y
−20.8%
From 52W high
−50.7%
From 52W low
+46.8%
$2.52
$7.50
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

TLSI stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores TriSalus Life Sciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 31 Oct 2026
28/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
66
Size
65
Revisions
43
Quality
42
Momentum
40
Growth
39
Value
34
Volatility
32
Issuance
15

Accruals (66): Reported profit is backed by cash, and the company is not expanding recklessly.

Issuance (15): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

TLSI stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on TLSI, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$2.00$4.00$6.00$8.00$10.00$12.00$14.00Jan 26Apr 26Jul 26Oct 26TLSIHigh $14Median $11Low $7

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says5 analysts
5 Buy0 Hold0 Sell
Low $7Median $11High $14

The green dot is the last close — the median target sits +197.3% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
23 Sept 2026HC Wainwright & Co.MaintainsBuy$11 → $12
9 Sept 2026HC Wainwright & Co.InitiatesBuy$11
9 Sept 2026HC Wainwright & Co.InitiatesBuy—
13 May 2026Lake StreetMaintainsBuy—
13 May 2026Lake StreetMaintainsBuy$10 → $8.00
9 Mar 2026Canaccord GenuityMaintainsBuy—
6 Mar 2026Canaccord GenuityMaintainsBuy—
17 Dec 2025Canaccord GenuityMaintainsBuy—
28 Mar 2025Canaccord GenuityMaintainsBuy—
13 Feb 2025Lake StreetInitiatesBuy—
24 Jan 2025Roth MKMReiteratesBuy—
17 Dec 2024Cantor FitzgeraldInitiatesOverweight—
15 Nov 2024Canaccord GenuityMaintainsBuy—
11 Nov 2024Roth MKMInitiatesBuy—
25 Oct 2024Northland Capital MarketsInitiatesOutperform—
16 Sept 2024OppenheimerInitiatesOutperform—
27 June 2024Canaccord GenuityMaintainsBuy—
30 May 2024Canaccord GenuityInitiatesBuy—
10 May 2024JonesTradingInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

TLSI appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

TLSI vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 30 Oct 2026, TriSalus Life Sciences, Inc. returned −20.8% against +12.4% for the S&P 500, dividends included.

TLSI vs S&P 500, last 12 monthsTotal return, rebased to 100
6080100120140160Jan 26Apr 26Jul 26Oct 26TLSIS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

TLSI analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

TriSalus Life Sciences, Inc. (TLSI) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
0.1×

Cheaper than 73% of US stocks

Price / sales
5.1×

Cheaper than 23% of US stocks

Price / book
34.6×

Cheaper than 3% of US stocks

EV / EBITDA
−7.2×

Cheaper than 84% of US stocks

Growth & margins
Revenue growth (YoY)
1.7%

Higher than 31% of US stocks

Earnings growth (YoY)
1.7%

Higher than 39% of US stocks

Gross margin
86.8%

Higher than 95% of US stocks

Operating margin
−86.0%

Higher than 14% of US stocks

Net margin
−62.6%

Higher than 9% of US stocks

Returns & dividend
Return on equity
205.8%

Higher than 98% of US stocks

Return on assets
−36.8%

Higher than 12% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

TriSalus Life Sciences, Inc. (TLSI) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • TriSalus Life Sciences, Inc. has a market value of $227.8M and an enterprise value of $216.0M.

  • Revenue in the twelve months to 30 June 2026: $45.1M. The latest quarter grew 1.7% year on year.

  • Net income over the same four quarters: −$28.2M, a −62.6% net margin.

  • Diluted earnings per share, trailing twelve months: $−1.30.

  • Free cash flow in the twelve months to 30 June 2026: −$23.3M.

  • Shares outstanding: 61.5M.

  • Trailing P/E: 0.1×; forward P/E: −14.8× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • TriSalus Life Sciences, Inc. employs 102 people — $442K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 31 Oct 2026

Data provided by Twelve Data

Peers

TLSI vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
TLSITriSalus Life Sciences, Inc.$227.8M28
ELMDElectromed, Inc.$225.5M91
LABStandard BioTools, Inc.$237.9M38
RXSTRxSight, Inc.$201.6M41
INGNInogen, Inc.$186.8M82
INFUInfuSystem Holdings, Inc.$280.2M100
TMCITreace Medical Concepts, Inc.$282.3M54

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own TriSalus Life Sciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest TLSI news & analysis

TriSalus Life Sciences to Participate in the Canaccord Genuity MedTech, Diagnostics, and Digital Health and Services Forum

Business Wire · 29 Oct 2026neutral

TriSalus Life Sciences announced that CEO and President Mary Szela and CFO David Patience will participate in the Canaccord Genuity MedTech, Diagnostics, and Digital Health and Services Forum.

Why it matters — The announcement provides TLSI watchers with information about planned participation by the company’s senior executives in an industry forum.

TriSalus Life Sciences to Host Third Quarter 2026 Financial Results Conference Call

Business Wire · 20 Oct 2026neutral

TriSalus Life Sciences announced it will host a conference call and webcast on November 10, 2026, at 8:30 a.m. Eastern to discuss financial results for the quarter ended September 30, 2026.

Why it matters — The call will provide TLSI watchers an opportunity to hear the company discuss its third-quarter financial results.

TriSalus Secures FDA Clearance For TriNav Advance as Stock Tests Key Support

Benzinga · 23 Sept 2026positive

The U.S. Food and Drug Administration granted 510(k) clearance for TriSalus Life Sciences' (NASDAQ:TLSI) TriNav Advance, the newest addition to its Pressure-Enabled Drug Delivery (PEDD) portfolio. This regulatory milestone comes as the company's stock tests key support.

Why it matters — A TLSI watcher would care because FDA clearance for a new product in the PEDD portfolio expands the company's commercial pipeline at a time when its stock is testing a key support level.

TriSalus Life Sciences, Lakefront Biotherapeutics, Editas Medicine And Other Big Stocks Moving Higher On Wednesday

Benzinga · 23 Sept 2026negative

U.S. stocks were lower, with the Nasdaq Composite falling over 100 points on Wednesday, while TriSalus Life Sciences was among the big stocks moving higher. The item is a brief market-movers note listing the gainers for the session.

Why it matters — A TLSI watcher would note that the company's shares gained ground on a day when the broader market, including the Nasdaq, declined.

TriSalus Life Sciences Receives FDA Clearance for TriNav® Advance, Strengthening Comprehensive Pressure-Enabled Drug Delivery™ (PEDD™) Portfolio for Liver Embolization

Business Wire · 22 Sept 2026positive

TriSalus Life Sciences announced it received U.S. FDA 510(k) clearance for TriNav® Advance, the newest addition to its Pressure-Enabled Drug Delivery (PEDD) portfolio for liver embolization. The clearance expands the company's PEDD product lineup.

Why it matters — FDA clearance of a new product in its core PEDD portfolio could broaden TriSalus's commercial offerings for liver embolization procedures.

FAQ

Frequently asked questions about TLSI stock

What is the TLSI stock price forecast for 2026-2027?

The 5 Wall Street analysts covering TriSalus Life Sciences, Inc. have a median 12-month price target of $11, with estimates ranging from $7 to $14. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is TLSI stock a buy right now?

Of the 5 analysts covering TriSalus Life Sciences, Inc., 5 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks TriSalus Life Sciences, Inc. 28 out of 100 across roughly 4,600 US stocks as at 31 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank TLSI?

As at 31 Oct 2026, TriSalus Life Sciences, Inc. ranks 28 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (66 of 100).

Will TLSI stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies +197.3% from the last close, and Ticker Nerd's factor model ranks TriSalus Life Sciences, Inc. 28 out of 100 as at 31 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the TLSI stock forecast for 2030?

No analyst covering TriSalus Life Sciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TLSI are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $7 to $14 over the next 12 months.

How has TLSI stock performed over the past year?

TriSalus Life Sciences, Inc. returned -20.8% over the 12 months to 30 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does TriSalus Life Sciences, Inc. do?

TriSalus Life Sciences, Inc. is an oncology-focused medical technology company developing drug delivery systems and immuno-oncology therapies for difficult-to-treat liver and pancreatic cancers.

What is the latest news on TLSI?

The most recent item we track (Business Wire, 29 Oct 2026): "TriSalus Life Sciences to Participate in the Canaccord Genuity MedTech, Diagnostics, and Digital Health and Services Forum". TriSalus Life Sciences announced that CEO and President Mary Szela and CFO David Patience will participate in the Canaccord Genuity MedTech, Diagnostics, and Digital Health and Services Forum.

Company

About TriSalus Life Sciences, Inc.

TriSalus Life Sciences, Inc. is an oncology-focused medical technology company developing drug delivery systems and immuno-oncology therapies for difficult-to-treat liver and pancreatic cancers. Its current product portfolio centers on Pressure-Enabled Drug Delivery (PEDD) platforms, including the TriNav infusion system for hepatic arterial procedures and the Pancreatic Retrograde Venous Infusion device. TriSalus also advances nelitolimod, an investigational immunotherapeutic designed to work alongside standard treatments in solid tumors. The company’s products and clinical programs are aimed at improving how therapies reach tumor sites, particularly where conventional delivery faces anatomical and physiological barriers. TriSalus Life Sciences, Inc. serves the interventional oncology and medical device markets, combining device-based delivery with oncology therapeutics to support physicians treating liver cancer, liver metastases, and pancreatic tumors.

CEO Ms. Mary T. Szela B.S.N., M.B.A. · 102 employees · United States · https://trisaluslifesci.com